IntroDuctIon
DCs are a heterogeneous population of immune cells that are essential mediators of immunity and tolerance [1] [2] [3] . Although DCs share a common ability to process and present antigen to naive T cells for the initiation of an immune response, they are not all identical, and their unique abilities and phenotypes are current areas of investigation. DCs from humans, which are best defined in the blood, are identified with BDCA markers. BDCA-2(CD303) + plasmacytoid DCs (pDCs) have the unique ability to rapidly produce abundant type I interferon (IFN) in response to viral infection 4 . BDCA-1(CD1c) + conventional DCs (cDCs) have been proposed to excel in CD4 + T-cell priming 5, 6 . Finally, BDCA-3(CD141) hi cDCs have the ability to capture dead cells and to cross-present exogenous antigen, offering a mechanism for priming CD8 + T cells specific for pathogens that do not directly infect DCs [7] [8] [9] [10] [11] [12] .
Whereas DC development has been studied extensively in mice 13 , the origin of human DCs and their relation to monocytes have been long debated. Our group has recently clarified the pathway for human DC hematopoiesis and shown its sequential origin from increasingly restricted but well-defined BM progenitors 14, 15 (Fig. 1) . Human granulocyte, monocyte and DC lineages originate from a common progenitor, the GMDP. GMDPs develop into a more restricted human MDP. MDPs give rise to monocytes and a CDP, which loses the potential to produce monocytes and is restricted to produce the three major subsets of DCs. These committed DC progenitors reside in BM, as well as in cord blood (CB), but not in blood or lymphoid tissues 14 . Finally, CDPs give rise to pDCs, as well as to a circulating cDC precursor cell (pre-cDC). Indeed, pre-cDCs develop in the BM, travel through the blood and differentiate into the two subsets of cDCs in peripheral lymphoid organs. In studies of human volunteers injected with Fms-related tyrosine kinase 3 ligand (FLT3L), we showed that human pre-cDCs are mobilized into the blood similarly to the more differentiated DC subsets 15 . Now that the lineagecommitted progenitors and immediate precursors for human DCs have been identified, studies to further define human DC hematopoiesis in health, disease and vaccine settings are possible, as well as the exploration of their potential utility in cellular immunotherapies. This can be facilitated by the use of this protocol, in which we describe flow cytometry assays to isolate and characterize DC progenitors. factor (SCF) receptor) and CD135 (FLT3 receptor) [16] [17] [18] [19] . However, the combination of these markers does not separate DC lineage-committed progenitors from multipotential progenitors. Moreover, it has been reported that a small fraction of cells that lack the expression of CD34 have progenitor potential 20 . These Lin − CD34 − cells probably represent precursor cells that have lost CD34 expression but that are still too immature to express lineage markers. Therefore, CD34, as well as the aforementioned markers, are not enough to further separate HSPCs, and additional markers are required to identify and isolate DC lineage-committed progenitors. As hematopoiesis relies on instructive cues from the BM niche such as hematopoietins, we hypothesized that the lineage potential of a progenitor might be determined by the set of growth factor receptors that it expresses. We showed that multipotential progenitors such as myeloid and lymphoid progenitors were heterogeneous, and they could be further fractionated using antibodies against receptors for granulocyte-macrophage colony-stimulating factor (GM-CSFR; CD116), macrophage colony-stimulating factor (M-CSFR; CD115) and interleukin-3 (IL-3R; CD123) (refs. 14,15). By using two slightly different antibody panels, we identified the following: (i) the human DC lineage-committed GMDP, MDP and CDP in the Lin − CD34 + fraction by combining antibodies against CD45RA, CD116, CD115 and CD123, as well as CD38 (ref. 14) , and (ii) the human pre-cDC, which was found in the Lin − CD34 − fraction and identified on the basis of the expression or lack of CD45RA, CD116, CD115 and CD123, as well as CD135 and CD117 (ref. 15 ). These progenitors are rare, which presents a challenge for the isolation of these cells.
When working with scarce cells, the simultaneous analysis of all four DC progenitors seems to be essential in order to provide a comprehensive view of DC hematopoiesis.
The proven multicolor panels presented in this protocol are based on our original studies 14, 15 with modifications enabling simultaneous assessment of all DC lineage-committed progenitors. As the common feature of progenitors that are capable of developing into DCs is surface expression of CD117 and CD135, the panel to define them includes the following: (i) antibodies specific to CD117 and CD135, as well as CD34, CD123, CD115, CD116 and CD45RA; (ii) antibodies specific to CD3 (T cell), CD19 (B cell), CD14 (monocytes), CD335 (natural killer (NK) cell), CD66b (granulocytes) and CD10 (lymphoid progenitors) to exclude specific lineages (Lin − ); (iii) antibodies specific to BDCA-1, BDCA-2 and BDCA-3 to exclude differentiated DCs (BDCA − ); (iv) a viability dye to exclude dead cells; and (v) an optional antibody specific to CD45 to visualize hematopoietic cells in nonhematopoietic tissues or in vitro cultures. All antibodies ( Table 1 ) and fluorochrome combinations ( Table 2) are commercially available, and experiments can be run on commonly available flow cytometers and flow sorters that are capable of multicolor analysis (see configurations in Tables 3 and 4) .
Defining human DC progenitors also required that we develop an efficient culture assay to study the ability of the progenitors to proliferate and differentiate in response to hematopoietic growth factors. Through systematic testing of different combinations of cytokines, as well as the use of mouse stromal cell lines, we showed that the in vitro differentiation of CD34 + HSPCs on MS-5 stromal cells in addition to FLT3L, SCF and GM-CSF cytokines (referred to as MS5+FSG herein) support the development of multiple lineages, including all three major human DC subsets. The resulting DC subsets resemble their blood counterparts both in gene expression and function 14 .
Experimental design
In this protocol, we give a flow cytometry-based workflow for (i) simultaneous detection of DC progenitors ( Table 2 , panel #1 and Fig. 2) , as well as their characterization ( Fig. 6 ). The procedure also covers various preparatory steps-isolation, freezing and thawing of mononuclear cells (MNCs) and hematopoietic differentiation on stromal cells.
Source tissue. The procedure can be performed on BM or CB samples. BM samples are typically obtained from elderly human donors; however, as age-related developmental changes may affect the composition of the progenitor compartment, CB cells can also be examined. As CB can be collected quite easily and cryopreserved, it is a good source of human progenitors. When these populations are purified and cultured in MS5+FSG, CB progenitors showed a differentiation potential similar to that exhibited by their BM counterparts 14, 15 .
Identification and characterization of DC progenitors. As described, human DC progenitors can be identified by the lack of lineage and BDCA markers and by combining CD123, CD34, CD115, CD116, CD45RA, CD117 and CD135 markers ( phycoerythrin (PE) channel for this purpose, as PE is bright, and most if not all antibodies are available in this color. Because CD135 staining is crucial in order to identify DC progenitors and because only CD135 PE works well in our hands, we decided to open the PE-Cy7 channel. PE-Cy7 is a tandem dye that can degrade in the presence of light and heat, and it will then emit in the parent dye channel (PE). However, by avoiding the exposure of samples to light and heat, this problem can be largely avoided. The gating procedure is the same as that previously described (Fig. 2b,c) , and the expression of CD11c, HLA-DR, CD38 and CD33 on DC progenitors is shown (Fig. 3b) . HLA-DR, whose expression is neither specific nor identical within the DC subsets, is also expressed by DC progenitors. CD11c, which is weakly expressed on cDCs and completely lacking on pDCs, is upregulated during DC development. CD38, which was initially used to identify multipotential progenitors 16 , as well as DC lineage-committed progenitors 14 , is also expressed by pre-cDCs. Because CD38 is expressed by all hematopoietic progenitors, we decided not to use it in our antibody panels and focus more on hematopoietin receptors that allow further separation of these cells. CD33, which is highly specific to the hematopoietic compartment, is expressed by all DC progenitors.
Isolation of progenitors.
We developed our flow cytometry strategy to identify DC progenitors on a 16-color flow cytometer (BD LSR II with blue, yellow/green, red, violet and UV lasers; see configuration in Table 3 ). To isolate DC progenitors, we adapted our panel to maximize the capacities of an 11-color cell sorter (BD Aria III with blue, yellow/green, red and violet lasers; see configuration in Table 4 ). This was done in part by restricting the number of channels used for lineage markers and by omitting the Live/Dead blue stain to exclude dead cells, relying only on
Of note, we do not include isotype controls in our immunostaining, as the use of fluorescent isotype controls is not completely accurate, and because we have ascertained that the monoclonal antibodies are specific by carefully titrating them and using fluorescence minus one (FMO) controls for gating.
In nonhematopoietic tissues, we recommend using CD45 to visualize hematopoietic progenitors, as it may be challenging to identify these rare cells among other cells such as autofluorescent macrophages. As shown in Figure 2d , most, if not all, DC progenitors express CD45. Therefore, one channel in antibody panel #1 remains open to the potential use of CD45.
As DC progenitors are rare cells in both BM and CB, their identification is a matter of carefully defining the gates separating positive and negative cells. As shown in Figure 2b ,c, the first step in the identification of human DC progenitors consists of excluding dead cells and debris by scatter gating. Live cells are then gated for singlets (side scatter(SSC)-W versus SSC-A; W = width, A = area), and dying cells are excluded on the basis of the uptake of the Live/Dead blue stain. The next step consists in the sequential exclusion of all lineage (CD3, CD19, CD14, CD66b, CD335 and CD10)-and BDCA (BDCA-1, BDCA-2 and BDCA-3)-expressing cells. To have a better resolution in our gates, we avoid as much as possible the use of a 'dump' channel containing all antibodies marking all excluded populations. Nonetheless, if the use of a 'dump' channel is considered to accommodate an additional antibody of interest (as done in Table 2 , panel #3), one should carefully titrate each antibody separately before combining them to avoid any compensation issues and difficulties in discriminating between negative cells and cells with low expression. The use of CD123 allows clear separation of cells that express a high level of CD123 (CD123 hi ) from cells that express no or a low level of CD123 (CD123 lo cells). CDPs are found within the CD123 hi cells by sequentially gating on CD135 + , CD116 + , CD45RA + and CD115 − cells. The CD123 lo gate is further analyzed by gating on CD34 + CD117 + (CD34 + ) cells or CD34 − CD117 + (CD34 − ) cells. Pre-cDCs are found in the CD34 − gate. Indeed, we first gate on cells that express CD135, CD116 and CD45RA but do not express CD115, and then exclude SSC-A-high cells, as these cells contain some monocyte precursors 15 . In contrast, the CD34 + population contains both GMDPs and MDPs. These progenitors are all CD135 + , CD116 − and CD45RA + ; expression of CD115 allows the separation of GMDPs (CD115 − cells) from MDPs (CD115 + cells). Even though the CD115 staining is very faint and it is not possible to get a clear-cut separation of positive and negative cells, the use of FMO control allows for proper gating on CD115 + cells (Fig. 2e) . Moreover, if we consider that lineage commitment occurs when the capacity to give rise to one cell type, e.g., monocyte and DC, is increased and the capacity to produce another cell type, e.g., granulocyte, is lost, dim CD115 expression is sufficient to separate cells with GMDP potential from cells with MDP potential.
To characterize DC progenitors, we use a related combination of antibodies ( exclusion by scatter gating ( Table 2 , panel #3). Moreover, the gating hierarchy while sorting is limited to a maximum of an eight-gate sort depth. This limit is intrinsic to the current generation of BD Aria III sorter hardware and firmware. To limit our gating strategy to eight steps (Fig. 4b) , we also removed the step to gate out the singlets (SSC-W versus SSC-A). The gating strategy to identify and sort all DC-defined progenitors simultaneously is shown in Figure 4c . (Fig. 5b) . Human CD45 antibody must be included in this panel, as it discriminates between human cells and mouse stromal cells, which are not entirely gated out by scatter analysis. Of note, BDCA markers are often used to classify human DCs. However, they are not strictly restricted to DCs; we therefore used them in combination with Clec9A for BDCA-3 hi cDCs, CD14 for BDCA-1 + cDCs and CD123 for BDCA-2 + pDCs.
To examine the proliferative potential of DC progenitors, we purified them from CB and stained them with carboxyfluorescein diacetate succinimidyl ester (CFSE) before culturing in MS5+FSG. By using a 14-color antibody panel ( Table 2 , panel #5) that includes CFSE, we were able to track the cells that were expanding in culture by CFSE dilution. As shown in Figure 6b ,c, all progenitors are expanding in culture, even though DC lineagecommitted progenitors-GMDP, MDP and CDP cells-have a greater proliferative capacity than DC immediate precursors, i.e., pre-cDCs. Moreover, BDCA-1 + and BDCA-3 hi cDCs differentiate as early as 12 h from CDP and pre-cDC progenitors.
Applications of the protocol
We believe that the protocol described here has multiple applications and a wide interdisciplinary scope including (i) further definition of human DC hematopoiesis in health, disease and vaccine settings, as well as (ii) evaluating DC progenitors' applications in therapeutic approaches.
Our protocol can be used as an initial tool to analyze normal or abnormal immunophenotypic changes during DC development in humans. For instance, it can facilitate the study of diseases involving aberrant DC hematopoiesis such as chronic myelogenous leukemia (CML) 21 or a newly identified form of primary immunodeficiency characterized by recurrent infections and disseminated bacille Calmette-Guérin (BCG) infection after vaccination in patients lacking GATA2 (ref. 22 ) and interferon regulatory factor 8 (IRF8) 23 . Because of their capacity to elicit and regulate immune responses, DCs are essential to any effort for vaccine development. Therefore, our protocol provides important tools to design and monitor and potentially improve vaccines that rely on DCs.
Finally, the methods described above can support the exploration of new cellular therapeutic approaches based on 
MaterIals

REAGENTS
Cell samples
Human samples can be obtained from national blood centers for CB and from local hospitals for BM ! cautIon Universal precautions must be taken while manipulating human specimens, and all experiments must be carried out in at least class II biological safety cabinets and using appropriate protection equipment. ! cautIon Parental informed consent (CB) or patient informed consent (BM) must be obtained before collection, and protocols must conform to your Institutional Review Board (IRB)'s guidelines. IRB-approved protocols usually require that the samples be anonymous and fully deidentified at the site of collection by hospital personnel.
Cell culture
Dulbecco 
DC progenitors including stem cell therapies focused on embryonic stem cells and induced pluripotent stem cells. The composition and the properties of the cells that are produced after in vitro differentiation of progenitors will differ considerably depending on the culture condition, and therefore this system can be used to evaluate DC progenitors to identify novel regulators of DC hematopoiesis or to test the toxicity of new drug candidates. Of note, therapeutic approaches based on human DC progenitors may require the development of a nonxenogeneic culture system; therefore, it would be good to explore the feasibility of expanding DC progenitors in an entirely human coculture system using either umbilical vein endothelial cells for CB progenitors or BM stromal cells for BM progenitors. 
Cryo 1 °C freezing container (Nalgene, cat. no. 5100-0001) LN2 storage systems (Thermo Scientific, cat. no. 7404) BD LSR II flow cytometer running DIVA 8.0, or equivalent (BD Biosciences, special order). Our LSR II is equipped with four lasers with a configuration allowing 16-color, 18-parameter flow cytometry ( Table 3) BD Aria III cell sorter running DIVA 8.0, or equivalent (BD Biosciences, special order). Our Aria III is equipped with three lasers with a configuration allowing 11-color, 13-parameter flow cytometry ( Table 4 (ii) Weigh the specimen for reference.  crItIcal step Samples can be stored at 4 °C for a few hours before starting the isolation procedure.  crItIcal step This protocol has been optimized for solid biopsies and not aspirates-i.e., a sample of the liquid portion of BM. 
3|
Centrifuge the mixture at 850g for 30 min at 20 °C in a swinging-bucket rotor with no brake.
4|
Aspirate the upper layer (yellow layer corresponding to the plasma, in the case of CB) leaving the mononuclear cell layer (white layer at the interphase between the Ficoll and the plasma) undisturbed. ? trouBlesHootInG 5| Carefully transfer each mononuclear cell layer using a sterile transfer pipette to a new 50-ml conical tube.
6|
Fill the 50-ml conical tubes with RPMI-1640, mix well, and centrifuge the tubes at 480g for 5 min at 20 °C with brake.
7|
Carefully remove the supernatant completely. Pool the pellet of all 50-ml conical tubes. Fill the 50-ml conical tube with RPMI-1640, mix it well and centrifuge it at 480g for 5 min at 20 °C with brake.  crItIcal step CB samples sometimes show substantial contamination of the interphase layer with red blood cells. In that case, resuspend the cell pellet in 5 ml of ACK lysing buffer. Allow it to stand for 5 min at 4 °C. Fill the 50-ml conical tube with RPMI-1640, mix it well and centrifuge it at 480g for 5 min at 20 °C with brake. Remove the supernatant; resuspend the cells in 50 ml of RPMI-1640 and centrifuge them once more at 480g for 5 min at 20 °C with brake. 
10|
Resuspend the cells at a density of 10 × 10 6 cells per ml in freezing medium.
11| Transfer 1 ml of cells in freezing medium per sterile cryogenic micro tube.  crItIcal step Label each tube clearly (date, sample name, cell concentration).  crItIcal step The optimal cell concentration for freezing is 10 × 10 6 cells per ml. However, you can go up to 50 × 10 6 cells per ml in case of large specimens.
12|
Put the cryogenic vial in a freezing container, and store it at −80 °C for 12-24 h before transferring it to the liquid nitrogen tank for long-term storage.  pause poInt Cells can be stored in liquid nitrogen for years.
thawing cB and BM Mncs • tIMInG 30 min 13| Add 10 ml of cold thawing medium in a 15-ml conical tube to thaw one vial or add 40 ml of cold thawing medium in a 50-ml conical tube to thaw up to ten vials.  crItIcal step To obtain the best possible survival, thawing of cells must be performed as quickly as possible, and the thawing medium should be cold to minimize heat shocks.
14|
Remove the vial from the liquid nitrogen tank, and hold it at room temperature until the sides are thawed but the center remains frozen.  crItIcal step Do not place the vial into a 37 °C water bath, as it is important not to dramatically heat-shock the cells.
15|
Transfer the contents of the vial (~1 ml) into a 15-ml conical tube containing cold thawing medium.
16|
Centrifuge the cells at 480g for 5 min at 20 °C.
17|
Resuspend the cells in staining buffer for extemporaneous use. 19| Aspirate the MS-5 growth medium and wash the cells twice with 10 ml of PBS.
20| Add 2 ml of trypsin-EDTA 0.05% (wt/vol) solution and incubate the cells for 2 min at 37 °C in a CO 2 cell incubator.  crItIcal step Inadequate washing of cells with PBS or using an old trypsin solution may result in partial detachment of cells from the dish.
21| Add 10 ml of MS-5 growth medium and collect the cells by pipetting.
22|
Transfer the cell suspension in a 15-ml conical tube and centrifuge it at 480g for 5 min at 20 °C.
23|
Aspirate the supernatant and resuspend the cells in 10 ml of MS-5 growth medium.
24|
Add 0.5 ml of cell suspension to 9.5 ml of MS-5 growth medium, and plate the cells onto a 10-cm tissue culture dish. Place the cells in a CO 2 cell incubator. If the upper layer is contaminated with RBCs, the samples-that is, upper layer and interphase-should be mixed and layered over a second batch of Ficoll in a new 50-ml conical tube. Repeat this step if necessary.
step 35
Post-thaw samples may clot. The cells are probably aggregating because of the release of DNA by cells dying during the freezing-thawing process. Include DNase such as benzonase (final concentration 25 U/ml) in thawing medium (Steps 13-17), as well as in staining buffer in Steps 36A(iii,iv), 36A(vii,viii) and 36B(ii,iii).
step 37
If you have no staining of compensation beads, it may be because not all compensation controls have been prepared in
Step 36. You must prepare a compensation control for each fluorochrome or conjugate if you are using tandem dyes. It may also be that you are not using the proper beads; use anti-mouse Igκ for mouse monoclonal antibodies and anti-rat Igκ for rat monoclonal antibodies.
step 38
If you have clogging of the sample line while acquiring samples, the cells are probably aggregating because of poor viability. We recommend resuspending the cells in sorting buffer that contains EDTA and filtering the cells using 5-ml polystyrene round-bottom tubes with cell-strainer caps.
step 39
If you have clogging of the sample line while sorting samples, the cells are probably aggregating because of poor viability. We recommend diluting the cells and filtering the sample again using a 5-ml polystyrene round-bottom tube with a cell-strainer cap.
